2013 ACG ANNUAL SCIENTIFIC MEETING
Symposia Sessions, Special Lectures and Oral Abstract Presentations

MONDAY MORNING, October 14, 2013

Simultaneous Symposia 1A: Management of Incurable Esophageal Disorders
Moderator: David A. Katzka, MD, FACG

- Maintenance Therapies in Eosinophilic Esophagitis
  David A. Katzka, MD, FACG ........................................ 20
  Define the role of maintenance strategies in patients with eosinophilic esophagitis.

- GERD: Management of Chronic Symptoms and Complications
  Joel E. Richter, MD, MACG ........................................ 36
  Describe the long term management of GERD.

- Achalasia/Spasm: Today and Tomorrow
  C. Prakash Gyawali, MD, FACG ...................................... 56
  Describe the current and future diagnostic and therapeutic tools of achalasia and esophageal spastic disorders.

Simultaneous Symposia 1B: The Future of IBD Treatment: 2013 and Beyond
Moderator: Ernest G. Seidman, MD, FACG

- Personalized Medicine in IBD
  Ernest G. Seidman, MD, FACG ........................................ 75
  Develop an understanding of the available genetic, serologic and drug levels.

- What to Do When Anti-TNFs Don't Work
  Bruce E. Sands, MD, FACG ............................................ 99
  Formulate a treatment strategy when patients do not respond to anti-TNFs.

- Quality of Care in IBD in 2013
  Thomas A. Ullman, MD, FACG .................................... 113
  Identify quality measures in IBD.

MONDAY AFTERNOON, October 14, 2013

The American Journal of Gastroenterology Lecture
The Emerging Role of the Microbiome in the Pathogenesis and Management of Inflammatory Bowel Disease
David T. Rubin, MD, FACG, and Stephen M. Collins, MBBS
Determine how the gut microbiome influences health and disease.

Please note: While evaluations for CME credit can ONLY be completed online (at www.amevaluations2013.gi.org), information corresponding to the online evaluation is provided on page 16 to assist you.

American College of Gastroenterology
6400 Goldsboro Road, Suite 200
Bethesda, MD 20817
Phone: 301.263.9000    Fax: 301.263.9025
www.gi.org

© 2013 American College of Gastroenterology
Simultaneous Symposia 2A: IBS or Not?
Moderator: Sheila E. Crowe, MD, FACG

Food Intolerances and IBS: Coexistent or Separate Entities?
Sheila E. Crowe, MD, FACG .................................................... 130
Describe the approach to determine whether food intolerances coexist with irritable bowel syndrome or are separate entities and how best to manage patients.

Implications of Gluten Intolerance and Celiac Disease in IBS
Joseph A. Murray, MD, FACG .................................................. 146
Discuss the approach of identifying the presence of gluten intolerance and celiac disease in patients with IBS-like symptoms and how best to manage them.

Overlap of IBS in IBD
Eamonn M. M. Quigley, MD, FACG ............................................. 167
Distinguish if IBS contributes to persistent symptoms in patients with treated or inactive IBD and discuss the mechanisms and treatment for patients with coexistent IBS and IBD.

Simultaneous Symposia 2B: Update for HCV in 2013
Moderator: Mitchell L. Shiffman, MD, FACG

New Treatments Approved and Awaiting Approval for Genotype 1 HCV
David E. Bernstein, MD, FACG .................................................. 188
Review new and awaiting treatment paradigms for genotype 1 HCV.

New Treatments Approved and Awaiting Approval for Genotype 2 and 3 HCV
Norah A. Terrault, MD, MPH, FACG ............................................. 207
Review the combination of polymerase inhibitor plus ribavirin therapy which may be approved by the FDA for genotype 2 and 3 in 2013.

Interferon: Old Fad or Here to Stay?
Mitchell L. Shiffman, MD, FACG .................................................. 220
Discuss the role of interferon based therapy in the era of polymerase inhibitors.

Simultaneous Symposia 2C: Video Forum: The Best ACG Cases of 2013
Moderators: David A. Greenwald, MD, FACG, Seth A. Gross, MD, FACG, and John R. Saltzman, MD, FACG
See page 5 for listing information

TUESDAY MORNING, October 15, 2013

Simultaneous Symposia 3A: What Are the Hot Pancreas Pearls for My Practice in 2013?
Moderator: Santhi Swaroop Vege, MD, FACG

New Classification, New Guidelines for Acute Pancreatitis
Santhi Swaroop Vege, MD, FACG .................................................. 226
Diagnose, predict, classify, assess, determine and treat patients with acute pancreatitis.

Chronic Pancreatitis: Pills, Stent, Cut or Transplant and the New American Guidelines
Darwin L. Conwell, MD, MS
Diagnose, predict, assess and determine the best modality of treatment.

Cancers – Adenocarcinoma and Neuroendocrine: Screening High Risk Groups and New Neuroendocrine Tumor Guidelines
Robert C. Kurtz, MD, FACG ..................................................... 253
Diagnose, stage and determine the role of screening high risk groups and follow new guidelines for diagnosis and treatment of neuroendocrine tumors.
Simultaneous Symposia 3B: Quality and Colonoscopy
Moderator: Aasma Shaukat, MD, MPH, FACG

Quality Reporting Is Here: What This Means for You
David A. Johnson, MD, MACG .......................................................... 279

Interpret PQRS and healthcare reform requirements and review resources for what to measure and how.

Technology and Interventions to Improve ADR
Aasma Shaukat, MD, MPH, FACG .................................................. 294

Identify the goals of ADR and review the role of technology and interventions geared towards improving ADRs for low performers.

Controversies in Screening and Surveillance Guidelines
Douglas J. Robertson, MD, MPH ..................................................... 312

Discuss if 10 year interval for screening may be too long and review controversies with surveillance guidelines.

TUESDAY AFTERNOON, October 15, 2013

Emily Couric Memorial Lecture
Can We Prevent Cancer in Barrett's Esophagus?
Nicholas J. Shaheen, MD, MPH, FACG

Understand the epidemiology of esophageal adenocarcinoma, state the evidence supporting endoscopic screening and surveillance of Barrett's esophagus, and know the novel methods of endoscopic screening and surveillance.

Simultaneous Symposia 4A: What's New in GI Bleeding
Moderator: John R. Saltzman, MD, FACG

Assessment, Triage and Timing of Endoscopy
John R. Saltzman, MD, FACG .......................................................... 325

Apply the new recommendations for transfusion goals and risk stratification in GI bleeding to improve patient triage.

Medical and Endoscopic Management of Upper GI Bleeding
David A. Greenwald, MD, FACG .................................................... 340

Apply the latest guidelines for medical management and perform current recommended endoscopic treatments to patients with GI bleeding.

Obscure and Mysterious GI Bleeding: What Test to Order and When
Jonathan A. Leighton, MD, FACG .................................................. 360

Apply the latest available information to choose the best test in managing patients with obscure GI bleeding.

Simultaneous Symposia 4B: Difficult Diarrheas: Running on Empty
Moderator: Lawrence R. Schiller, MD, FACG

Enteropathies: When the Mucosa Isn't Working
Carol E. Semrad, MD, FACG .......................................................... 379

Understand the principles of normal fluid and electrolyte intestinal absorption; Diagnose and manage diseases that damage the small bowel mucosa.

Bacterial Overgrowth: Getting the Bugs Out
Lawrence R. Schiller, MD, FACG .................................................... 396

Understand the adverse effect of bacterial growth on digestion and absorption; Recognize and manage diseases that predispose to bacterial overgrowth.

Bile Acid Malabsorption: When Detergents Are Too Much
Joseph H. Sellin, MD, FACG .......................................................... 408

Learn new mechanisms by which bile salts cause diarrhea; Diagnose and manage the different types of bile acid diarrhea.
WEDNESDAY MORNING, October 16, 2013

David Y. Graham Lecture

Leadership in Medicine 2013: Do We Need a New Approach?
Eamonn M. M. Quigley, MD, FACG .......................................................... 431
Know what organizational and governance changes have occurred in the medical environment and how leadership styles can successfully adapt to this new context; be able to implement a number of methods to improve leadership capabilities, and understand the fundamental importance of communication to good leadership.

Simultaneous Symposia 5A: Debate – Where’s the Finish Line? The Moving Target of IBD Treatment Endpoints
Moderator: Miguel D. Regueiro, MD, FACG

Case Presentation
Miguel D. Regueiro, MD, FACG ............................................................. 454
Learn the differences in outcomes for treating to symptom improvement compared with mucosal healing.

Treat to Symptoms
William J. Tremaine, MD, FACG ............................................................ 459
Describe outcomes of IBD treatment endpoints and explain the role of symptom response.

Treat to Target
David T. Rubin, MD, FACG ................................................................. 474
Specify the various indices utilized to determine treatment success in IBD (clinical, biomarkers, and mucosal healing).

Simultaneous Symposia 5B: Malpractice Issues for the Gastroenterologist
Moderator: John Baillie, MB, ChB, FACG

The Risk of Supervising Mid-level Providers: What You Need to Know
Andrew D. Feld, MD, JD, FACG ............................................................. 490
Understand the medico-legal risk of supervising non-physicians.

Stopping Anti-platelet Agent: Will You Cause a Stroke?
Glenn M. Eisen, MD, MPH ................................................................. 505
Review the risks of stopping anti-coagulation for elective procedures.

How to Professionally and Personally Survive a Malpractice Suit
John Baillie, MB, ChB, FACG .............................................................. 519
Establish strategies to deal with the emotional and professional aspects of a lawsuit.
### ORAL ABSTRACT PRESENTATIONS

**Monday, October 14, 2013**

<table>
<thead>
<tr>
<th>Abstract</th>
<th>Title</th>
<th>page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Do CRNAs Need Onsite MD Anesthesia Supervision for Safe Propofol Sedation in an Ambulatory Endoscopy Center (AEC)? A Comparison of 2 Sedation Models: CRNA Alone and CRNA with MD Anesthesia Supervision in 99,818 Consecutive Procedures</td>
<td>532</td>
</tr>
<tr>
<td>2.</td>
<td>Electrical Stimulation Therapy (EST) of the Lower Esophageal Sphincter (LES) – An Effective Therapy for Refractory GERD – Interim Results of an International Multicenter Trial</td>
<td>532</td>
</tr>
<tr>
<td>3.</td>
<td>Intestinal Metaplasia of the Stomach Is Associated with an Increased Risk of Gastric Cancer in a Western Population</td>
<td>533</td>
</tr>
<tr>
<td>4.</td>
<td>Vascular Endothelial Growth Factor Levels in Bile Distinguishes Pancreatic Cancer from other Etiologies of Biliary Stricture</td>
<td>534</td>
</tr>
<tr>
<td>5.</td>
<td>The CCFA National Survey of Health Care Access in Inflammatory Bowel Disease (IBD)</td>
<td>535</td>
</tr>
<tr>
<td>6.</td>
<td>Long Term Mortality Following Screening for Colorectal Cancer: Results from the Minnesota Fecal Occult Blood Trial</td>
<td>535</td>
</tr>
<tr>
<td>8.</td>
<td>Anti-vinculin Antibodies: Multicenter Validation of a Diagnostic Blood Test for Irritable Bowel Syndrome</td>
<td>536</td>
</tr>
<tr>
<td>9.</td>
<td>Cost Effectiveness of Competing Strategies for Recurrent <em>Clostridium difficile</em> Infection</td>
<td>537</td>
</tr>
<tr>
<td>10.</td>
<td>Fecal Microbiota Transplantation (FMT) for Treatment of <em>Clostridium difficile</em> Infection (CDI) in Immunocompromised Patients</td>
<td>537</td>
</tr>
<tr>
<td>11.</td>
<td>Epidemiology of Microvesicular and Goblet Cell Hyperplastic Polyps</td>
<td>538</td>
</tr>
<tr>
<td>12.</td>
<td>Variability in Adenoma Detection Rate and Withdrawal Time, and Effect of Performance Improvement Interventions Over Time</td>
<td>539</td>
</tr>
<tr>
<td>13.</td>
<td>Incidence of Colorectal Cancer after a Negative Colonoscopy</td>
<td>540</td>
</tr>
<tr>
<td>14.</td>
<td>Improved Detection and More Accurate Surveillance Intervals with Fuse™ Colonoscopy</td>
<td>540</td>
</tr>
<tr>
<td>15.</td>
<td>The Evaluation of Hepatic Fibrosis Scores in Children with Nonalcoholic Fatty Liver Disease</td>
<td>541</td>
</tr>
<tr>
<td>16.</td>
<td>Rate and Predictors of Possible Missed Esophageal and Gastric Cancers after Esophagogastroduodenoscopy in the United States</td>
<td>541</td>
</tr>
<tr>
<td>18.</td>
<td>Factors Influencing Safety of Sedation in a Large Cohort of Patients Undergoing Advanced Endoscopic Procedures</td>
<td>542</td>
</tr>
</tbody>
</table>

**Video 1.** Direct Endoscopic Mediastinal Necrosectomy

**Video 2.** EUS-guided Full-thickness Resection of a Gastric Subepithelial Tumor and Endoscopic Suture Closure of Post-resection Defect

**Video 3.** Full Thickness en bloc Endoscopic Resection of Muscularis Based Subepithelial Tumors (SETs)

**Video 4.** Percutaneous Endoscopic Sigmoidopexy with T-fasteners for Management of Surgically Inoperable Sigmoid Volvulus

**Video 5.** Total Endoscopic Removal of an Eroded Gastric Bypass Fobi Ring

**Video 6.** Volumetric Laser Endomicroscopy (VLE): An OFDI Case Study of Barrett's Esophagus with Dysplasia

**Video 7.** Novel Technique for Removal of Ingested Neodymium Magnets in Pediatrics
<table>
<thead>
<tr>
<th>Abstract</th>
<th>Title</th>
<th>page</th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td>Increased Incidence of Colorectal Cancer in Patients with Prior Endometrial Cancer: A Population Based U.S. Study</td>
<td>547</td>
</tr>
<tr>
<td>20</td>
<td>Impact of Member Incentives on Colorectal Cancer Screening</td>
<td>548</td>
</tr>
<tr>
<td>21</td>
<td>A Novel Balloon-colonoscope for Increased Polyp/Adenoma Detection Rate: Results of a Randomized Tandem Study</td>
<td>548</td>
</tr>
<tr>
<td>22</td>
<td>Excellent (83%) Colorectal Cancer Prevention Due to an Optimized Colonoscopy Method</td>
<td>549</td>
</tr>
<tr>
<td>23</td>
<td>Risk and Benefits of Surveillance Colonoscopy in Patients 75 and Older</td>
<td>550</td>
</tr>
<tr>
<td>24</td>
<td>Sensitivity, Specificity, and Stability of Seromarkers in a Prospective, Population-based Cohort of Newly Diagnosed Inflammatory Bowel Disease (IBD)</td>
<td>550</td>
</tr>
<tr>
<td>25</td>
<td>Feasibility of Endoscopic Assessment and Treating to Target to Achieve Mucosal Healing in Crohn’s Disease</td>
<td>551</td>
</tr>
<tr>
<td>26</td>
<td>Role of Non-steroidal Anti-inflammatory Drugs in Exacerbations of Inflammatory Bowel Disease</td>
<td>552</td>
</tr>
<tr>
<td>27</td>
<td>Treatment for CMV Infection in IBD Inpatients Does Not Change Clinical Outcomes</td>
<td>552</td>
</tr>
<tr>
<td>28</td>
<td>Randomized Study Comparing Peroral Endoscopic Myotomy, Botulinum Toxin Infection and Balloon Dilation for Achalasia: One Year Follow-up</td>
<td>553</td>
</tr>
<tr>
<td>29</td>
<td>Per Oral Endoscopic Myotomy (POEM) for Achalasia: Excellent Long Term Safety, Efficacy and Durability in a Large Single Center 4 Year Series</td>
<td>554</td>
</tr>
<tr>
<td>30</td>
<td>Is Second Look for Staging of Newly Diagnosed Esophageal Cancer Necessary?</td>
<td>554</td>
</tr>
<tr>
<td>31</td>
<td>Addition of EUS-FNA and On-site Cytology to EUS-FNB Increased Procedure Time but Not Diagnostic Accuracy</td>
<td>555</td>
</tr>
<tr>
<td>32</td>
<td>Repeat Endoscopic Ultrasound Guided Celiac Plexus Block and Neurolysis: What Is the Efficacy and Safety?</td>
<td>556</td>
</tr>
<tr>
<td>33</td>
<td>Deep Enteroscopy with a Conventional Colonoscope: Initial Multicenter Study Using the NaviAid™ Balloon System</td>
<td>556</td>
</tr>
<tr>
<td>34</td>
<td>Cecal Intubation Times with Colonoscopes Incorporating Passive Bending and High Force Transmission Technology: A Multicenter Randomized Controlled Trial</td>
<td>557</td>
</tr>
<tr>
<td>35</td>
<td>Naloxegol Symptom Responder Rates in Patients with Opioid Induced Constipation: A Multicenter Randomized Controlled Trial</td>
<td>558</td>
</tr>
<tr>
<td>36</td>
<td>Results of the EPISOD Multicenter Sham-controlled Trial of Sphincterotomy in Patients with Suspected Sphincter of Oddi Dysfunction Type III</td>
<td>558</td>
</tr>
<tr>
<td>37</td>
<td>Faldaprevir plus Pegylated Interferon Alfa-2a and Ribavirin in Chronic HCV Genotype-1 Treatment Naive Patients: Final Results from STARTVersol, a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial</td>
<td>559</td>
</tr>
<tr>
<td>38</td>
<td>Sofosbuvir + Ribavirin with or without Peginterferon Is Well Tolerated and Associated with High SVR Rates: Integrated Results from Phase 3 Trials in HCV Genotype 1-6</td>
<td>561</td>
</tr>
<tr>
<td>39</td>
<td>Safety and Efficacy of Interferon-free Regimens of ABT-450/r, ABT-267, ABT-333 +/- Ribavirin in Patients with Chronic HCV GTI Infection: Results from the Aviator Study</td>
<td>562</td>
</tr>
<tr>
<td>40</td>
<td>Novel Community Based Hepatitis B Screening Program Among African Immigrants with Linkage to Care by a Culturally Targeted Patient Navigator</td>
<td>563</td>
</tr>
<tr>
<td>41</td>
<td>Adherence to Cirrhosis Complication Quality Bundles Is Poor and Not Associated with Reduced 30-day Readmissions</td>
<td>563</td>
</tr>
<tr>
<td>42</td>
<td>PNPLA3 Gene Polymorphism Is Associated with Alcohol Related Liver Injury with Increased Progression to Cirrhosis and Hepatocellular Carcinoma</td>
<td>565</td>
</tr>
<tr>
<td>43</td>
<td>Hepatocellular Carcinoma in Non-cirrhotic Liver at a Single VA Medical Center (VAMC)</td>
<td>566</td>
</tr>
<tr>
<td>44</td>
<td>Effects of the Transjugular Intrahepatic Portosystemic Shunt on Portal Vein Thrombosis in Patients with Liver Cirrhosis</td>
<td>566</td>
</tr>
<tr>
<td>45</td>
<td>Delayed Paracentesis Is Associated with Increased In-hospital Mortality in Patients with Spontaneous Bacterial Peritonitis</td>
<td>567</td>
</tr>
<tr>
<td>46</td>
<td>Influence of Reflux and Central Adiposity on Intercellular Space in Squamous Esophageal Epithelium</td>
<td>567</td>
</tr>
<tr>
<td>47</td>
<td>A Novel Sleep Assist Device Prevents Gastroesophageal Reflux: A Randomized Controlled Trial</td>
<td>569</td>
</tr>
</tbody>
</table>
48. Obesity and Waist Belt Distort the Esophagogastric Junction and Induce Intraspincteric Acid Reflux 570

49. Gender Disparities in Remission of Esophageal Intestinal Metaplasia after Radio-frequency Ablation 571

50. Esophageal Eosinophilia and Eosinophilic Esophagitis Are Increased in Rural Areas with Low Population Density: Results from a National Pathology Database 571

51. Racial/Ethnic Disparities in Cardia vs. Non-cardia Gastric Cancer Incidence and Survival in the United States 572

52. BUN-Creatinine Ratio Does What Glasgow-Blatchford or Other Prediction Scores Do Not: Predicts High Risk Lesions and Endoscopic Intervention for Non-variceal Upper GI Bleed 572

53. Gastric Electrical Stimulation Improves Long Term Outcomes of Patients with Gastroparesis 573

54. No Paper #54

Wednesday, October 16, 2013

55. Lack of Pituitary Adenylate-Cyclase Activating Peptide (PACAP) Receptor Leads to Failure of Active Ghrelin Suppression after Feeding 575

56. Separate Duodenal Bulb Biopsies Increase Detection of Abnormal Histology but Do Not Increase Yield of Celiac Disease in All-comers to Endoscopy 575

57. Duodenal Aspirates for Small Bowel Intestinal Overgrowth (SIBO): Yield, PPIs and Immediate Outcomes after Treatment 576

58. Female Gender Impacts Mortality and Length of Stay in Acute Pancreatitis in the United States: A Report of the National Inpatient Sample 577

59. A Model Based on Changes in Serum Amylase Levels during the First Two Days of Admission Predicts Severity of Acute Pancreatitis (AP) 578

60. Sacrificing Affordability in the Name of Proving Efficacy: The Case of Pancreatic Enzyme Replacement Therapy 579

61. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware and Frequency in Genetic Mutations in Pancreatic Cancer Kindreds 579

62. Validation of 5 Point Scoring System for Prediction of Malignancy in IPMN 580

63. A Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of Common Bile Duct (CBD) 580

64. Correlation of Intestinal Tissue Anti-TNF Drug Levels with Endoscopic Disease Activity in Patients with Inflammatory Bowel Disease: The ATLAS Study 582

65. Novel Gene-Gene and Gene-Environment Interactions in Ulcerative Colitis 582

66. U.S. Readmission Rates and Costs Following Hospitalization for Inflammatory Bowel Disease 584

67. Inflammatory Bowel Disease Patients with Poor Sleep Quality also Have a Poor Quality of Life: A Correlation between the Pittsburgh Sleep Quality Index and Short Inflammatory Bowel Disease Questionnaire 584

68. Impact of DXA Screening in Preventing Fragility Fractures Among Ulcerative Colitis Patients Treated with Corticosteroids 585

69. Risk of Non-melanoma Skin Cancer in Ulcerative Colitis Patients Treated with Thiopurines: A Nationwide Retrospective Cohort 587

70. The Incidence of Influenza and Influenza-related Complications in Inflammatory Bowel Disease Patients Across the United States 588

71. Vercirnon, an Oral CCR9 Antagonist, as Induction Therapy in Active Crohn’s Disease: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial 589